Anthracyclines inhibit -1 programmed ribosomal frameshifting and restrict HCoV-OC43 infection

This study identifies anthracycline compounds as effective antivirals against HCoV-OC43 by demonstrating that they selectively bind to and inhibit the virus's -1 programmed ribosomal frameshifting element, thereby reducing infection.

The Gist

Imagine your body is a bustling city, and viruses are like sneaky construction crews trying to build illegal skyscrapers (new viruses) to take over the neighborhood. One of the most common crews causing trouble in the winter is the Human Coronavirus OC43 (HCoV-OC43), the usual suspect behind seasonal colds.

This paper is about a team of scientists who discovered that some old cancer-fighting drugs (called Anthracyclines) might actually be secret agents that can stop these viral construction crews in their tracks.

Here is the story of how they did it, explained with some everyday analogies:

1. The Viral "Magic Trick" (The Frameshift)

To build their skyscrapers, viruses need a specific set of blueprints. But the virus has a limited amount of paper, so it uses a clever trick called -1 Programmed Ribosomal Frameshifting (-1 PRF).

Think of the virus's genetic code as a sentence written without spaces:

THECATSATONTHEMAT

Normally, your cell's "reader" (the ribosome) reads it in groups of three letters: THE CAT SAT ON THE MAT.

But the virus has a special "slippery spot" in the middle of the sentence. When the reader hits this spot, it slips backward one letter, changing the whole meaning:

THE CAT SAT ON THE MAT becomes THE CAT SAT ON THE MAT (but shifted).

This slip allows the virus to read a different set of instructions, which are essential for building its replication machine. If the virus doesn't slip at the right time, it builds the wrong parts, and the skyscraper collapses.

2. The Discovery: Old Drugs, New Tricks

The scientists asked: "Can we find a drug that jams this slippery spot so the virus can't slip?"

They tested a library of 25 different drugs, mostly focusing on Anthracyclines (common chemotherapy drugs like Idarubicin and Nogalamycin).

• The Result: They found that these cancer drugs acted like mud on the slippery spot. When they added the drugs to cells infected with HCoV-OC43, the virus couldn't slip. The construction crew got confused, built the wrong parts, and the infection stopped.
• The Catch: The drugs didn't kill the virus's blueprints (RNA); they just stopped the workers from reading them correctly. It's like putting a "Do Not Read" sign on the blueprint rather than burning the paper.

3. The Twist: Not All Viruses Are the Same

The scientists then tested these same drugs on SARS-CoV-2 (the virus that causes COVID-19).

• The Surprise: The drugs still stopped the virus from infecting cells! But here's the weird part: They didn't stop the "slippery trick" in SARS-CoV-2.
• The Metaphor: Imagine the HCoV-OC43 virus is wearing a red hat and the SARS-CoV-2 virus is wearing a blue hat. The drug is a magnet that sticks to the red hat, jamming the mechanism. But the blue hat is made of a different material, so the magnet doesn't stick to the mechanism. Yet, for some other reason, the magnet still stops the blue-hat crew from entering the building.

This tells us that while these drugs work against both viruses, they use different weapons against each one. Against the seasonal cold, they jam the "slippery trick." Against COVID, they might be doing something else entirely (like blocking the front door).

4. How They Proved It

To be sure the drugs were actually sticking to the "slippery spot" and not just poisoning the cell, they did a few clever tests:

• The Light Test: Anthracyclines naturally glow under a special light. When the scientists mixed the drug with the viral "slippery spot" RNA, the light went out (quenched). This proved the drug was physically hugging the RNA.
• The Shape Test: They checked if the drug changed the shape of the RNA. Surprisingly, the shape stayed the same. This suggests the drug might be stabilizing the structure in a way that makes it too rigid to slip, rather than breaking it.

Why Does This Matter?

1. Repurposing is Fast: These drugs already exist and are approved for cancer. If we can tweak them to fight viruses, we don't have to wait years to develop new medicines from scratch.
2. Targeting the Weakness: The "slippery spot" is a very old, unchanging part of the virus. It's like a weak foundation in a building. If you jam that, the virus can't easily evolve a new trick to bypass it.
3. Helping Vulnerable People: Seasonal coronaviruses can be deadly for the elderly and people with weak immune systems (like cancer patients). Finding a way to stop them is crucial.

The Bottom Line

This paper is like finding a universal key that fits two different locks, but works in two different ways. The scientists found that old cancer drugs can jam the "slippery mechanism" of the seasonal cold virus, stopping it from building new copies. While it works differently on the COVID virus, the discovery opens a exciting new door for using existing medicines to fight future viral outbreaks.

In short: They found a way to put "mud" on the virus's slippery slide, making it trip and fall before it can take over your cells.

Technical Summary

1. Problem Statement

• Clinical Gap: Human coronavirus OC43 (HCoV-OC43) is a leading cause of seasonal colds but can cause severe disease in the elderly and immunocompromised. Currently, there are no approved antiviral drugs specifically targeting HCoV-OC43.
• Therapeutic Target: Coronaviruses utilize -1 programmed ribosomal frameshifting (-1 PRF) to regulate the stoichiometry of viral proteins. This process is mediated by a highly conserved RNA structure called the Frameshifting Stimulation Element (FSE), which forms a three-stemmed pseudoknot. Disrupting the balance between ORF1a and ORF1b translation products cripples viral replication.
• Hypothesis: The authors hypothesized that repurposing existing small-molecule drugs, specifically aminoglycosides and anthracyclines (known RNA binders), could inhibit the FSE, disrupt -1 PRF, and thereby reduce viral infection.

2. Methodology

The study employed a multi-faceted approach combining in vitro biochemical assays, cell-based infection models, and structural biology techniques:

• Compound Screening: A library of 25 aminoglycosides and anthracyclines was screened against HCoV-OC43 infection in HCT-8 cells using immunofluorescence microscopy to quantify viral nucleoprotein.
• In Vitro Translation Assays:
  • Dual Luciferase Reporter: A construct containing the viral FSE between Renilla and Firefly luciferase genes was used. Firefly expression only occurs upon -1 PRF. The ratio of Firefly/Renilla activity quantified frameshifting efficiency.
  • Flag-Tag Reporter: A similar construct using a Flag-tag allowed detection of short (0-frame) vs. long (-1-frame) translation products via Western blot.
• Viral Infection Models:
  • HCoV-OC43: Infected HCT-8 cells treated with compounds; viral load measured via immunofluorescence and RT-qPCR.
  • SARS-CoV-2: Various strains (Wuhan, Delta, Omicron BA.2, XBB.1.9.2.5.1.3) infected A549-ACE2 and Vero-E6 cells. Protein expression of NSP8 (upstream of FSE) and NSP12/RdRP (downstream of FSE) was analyzed via Western blot to assess PRF inhibition.
• Structural Analysis:
  • DMS-MaPseq: Dimethyl sulfate mutational profiling with sequencing was used to determine if anthracyclines altered the secondary/tertiary structure of the FSE RNA.
  • Fluorescence Quenching: Intrinsic fluorescence of anthracyclines was measured to confirm direct binding to the FSE RNA (quenching indicates binding).
• Controls: Valrubicin (inactive anthracycline) and Merafloxacin (known PRF inhibitor for SARS-CoV-2) were used as negative and positive controls, respectively.

3. Key Results

A. Inhibition of HCoV-OC43

• Antiviral Activity: Among 25 compounds, anthracyclines (specifically Idarubicin, Nogalamycin, Daunorubicin, Epirubicin) showed potent antiviral effects. Idarubicin was the most effective, showing near-complete inhibition at 5 µM (IC50 ≈ 2.4 µM).
• Mechanism of Action:
  • Protein vs. RNA: While viral protein levels dropped significantly, viral RNA levels decreased only marginally (<50% at 10 µM). This suggests the drugs act post-transcriptionally (on translation) rather than inhibiting RNA replication.
  • PRF Inhibition: In in vitro translation assays, Idarubicin and Nogalamycin significantly reduced -1 PRF efficiency (IC50 for PRF inhibition: Idarubicin ≈ 20.5 µM; Nogalamycin ≈ 35.4 µM).
  • Binding: Fluorescence quenching assays confirmed that active anthracyclines (Idarubicin, Nogalamycin, Daunorubicin) bind directly to the HCoV-OC43 FSE, whereas inactive Valrubicin did not.
  • Structural Stability: DMS-MaPseq revealed that binding did not disrupt the pseudoknot structure; instead, the drugs likely stabilize the existing structure, preventing the ribosome from frameshifting.

B. Inhibition of SARS-CoV-2

• Antiviral Activity: Anthracyclines (particularly Nogalamycin) also reduced SARS-CoV-2 infection in A549-ACE2 cells across multiple variants (Delta, Omicron, XBB).
• Divergent Mechanism:
  • Unlike HCoV-OC43, anthracyclines did not inhibit -1 PRF in SARS-CoV-2. Western blots showed no change in the NSP12/NSP8 ratio in infected cells treated with the drugs.
  • In vitro translation assays with the SARS-CoV-2 FSE confirmed no reduction in frameshifting.
  • Conclusion: The antiviral effect against SARS-CoV-2 is likely mediated by a different mechanism (e.g., entry inhibition or immune stimulation) rather than FSE targeting.

C. Specificity

• The study demonstrated that Idarubicin selectively targets the HCoV-OC43 FSE but not the SARS-CoV-2 FSE, despite the structural similarities between the two pseudoknots. This suggests subtle sequence/structural differences dictate drug specificity.

4. Key Contributions

1. Drug Repurposing: Identified a specific subset of anthracyclines (Idarubicin, Nogalamycin) as potent inhibitors of HCoV-OC43.
2. Mechanistic Insight: Established that these drugs inhibit HCoV-OC43 by directly binding to and stabilizing the FSE, thereby reducing -1 PRF efficiency and disrupting the ORF1a/ORF1b protein ratio.
3. Differentiation of Mechanisms: Clarified that while anthracyclines inhibit both HCoV-OC43 and SARS-CoV-2, the mechanism differs: FSE inhibition for HCoV-OC43 vs. non-FSE mechanisms for SARS-CoV-2.
4. Methodological Validation: Validated the use of in vitro translation assays to distinguish between direct PRF inhibition and general translational toxicity or indirect cellular effects.

5. Significance and Implications

• Therapeutic Potential: The findings provide a robust framework for developing new antivirals targeting the conserved FSE of seasonal coronaviruses, a group currently lacking specific treatments.
• Target Validation: Confirms the FSE as a viable drug target, with anthracyclines serving as a chemical scaffold for future optimization.
• Clinical Relevance: Given the high prevalence of HCoV-OC43 in immunocompromised and elderly populations, repurposing anthracyclines (already in clinical use for cancer) could offer immediate therapeutic options, potentially with reduced toxicity through combinatory therapies.
• Future Directions: The study highlights the need to further investigate the specific structural interactions between anthracyclines and the HCoV-OC43 FSE to design more potent, virus-specific inhibitors that avoid off-target effects on host translation.